IPN10200 Placebo

Preclinical

IPN10200 Placebo is one of 3 therapeutic programs targeting Moderate to Severe Upper Facial Lines. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Moderate to Severe Upper Facial LinesActive, not recruiting

Moderate to Severe Upper Facial LinesPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Moderate to Severe Upper Facial Lines

#DrugCompanyPhaseTrials

Corabotase

Ipsen

Preclinical

1 2

Dysport

Ipsen

Preclinical

1 3

IPN10200 Placebo

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Moderate to Severe Upper Facial Lines

NCT04821089

Clinical

Trials by Indication[1]

Moderate to Severe Upper Facial Lines1 trial

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults

Active, not recruiting· Ipsen logo

Ipsen·Preclinical·NCT04821089·727 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPN10200 Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for IPN10200 Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Ipsen

IPN10200 Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Moderate to Severe Upper Facial Lines1 trial

References

Drug Info

Quick Facts

Related News